EUCTR2008-008004-41-DE进行中（未招募）1 期
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Each patient must meet the following criteria to be enrolled in this study.
- •1. Willing and able to provide written informed consent
- •2. Written Authorization for Use and Release of Health and Research Study information (US sites only) or Data Protection Consent (European sites only) has been obtained
- •3. Male aged 18 years and above
- •4. Histologically or cytologically confirmed adenocarcinoma of the prostate
- •5. Metastatic disease documented by positive bone scan or metastatic lesions other than liver or visceral metastasis on CT, MRI. If lymph node metastasis is the only evidence of metastasis, it must be = 2 cm in diameter
- •6. Prostate cancer progression documented by PSA according to PCWG2 or radiographic progression according to modified RECIST criteria
- •7. Asymptomatic or mildly symptomatic from prostate cancer. A score of 0-1 on BPI-SF Question #3 (worst pain in last 24 hours) will be considered asymptomatic, and a score of 2-3 will be considered mildly symptomatic.
- •8. Surgically or medically castrated, with testosterone levels of < 50 ng/dL (< 2.0 nM). If the patient is being treated with LHRH agonists (patient who have not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and must be continued throughout the study.
- •9. Previous anti-androgen therapy and progression after withdrawal. Patients who received combined androgen blockade with an anti-androgen must have shown PSA progression after discontinuing the anti-androgen prior to enrollment (= 4 weeks since last flutamide, = 6 weeks since last bicalutamide or nilutamide).
- •10. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •11. Hemoglobin = 10.0 g/dL independent of transfusion
- •12. Platelet count =100,000/µL
- •13. Serum albumin = 3.5 g/dL
- •14. Serum creatinine < 1.5 x ULN or a calculated creatinine clearance = 60 mL/min
- •15. Serum potassium = 3.5 mmol/L
- •16. Liver function:
- •i. Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert’s disease)
- •ii. AST or ALT < 2.5 x ULN
- •17. Able to swallow the study drug whole as a tablet
- •18. Life expectancy of at least 6 months
- •19. Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration.
- •Eligibility Criteria for Patients Formerly on Placebo who Crossover to Abiraterone Acetate from Long-term Follow-up
- •1. Previous participation in the placebo arm of Study COU-AA-302 and currently in long term follow-up.
- •2. Patient is willing and able to provide written informed consent to receive abiraterone acetate therapy.
- •3. Investigator's assessment that abiraterone acetate therapy will be safe and beneficial.
- •4. If subject received therapy with mitoxantrone, MUGA/ECHO must be =50%.
- •5. Not currently receiving prostate cancer treatment other than LHRH analogues. Patients who have received chemotherapy should have received the last dose of chemotherapy at least 4 weeks before Cycle 1 Day 1 of crossover.
- •6. The safety of concomitant cytotoxic chemotherapy and abiraterone acetate treatment has not been established. No cytoxtoxic chemotherapy should be administered while the patient is receiving abiraterone acetate treatment.
- •7. ECOG performance status of 0,1, or 2. Treatment will be continued until the investigator determines that the p
排除标准
- •Patients who meet any of the following criteria will be excluded from the study:
- •1.Active infection or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated.
- •2.Any chronic medical condition requiring a higher dose of corticosteroid than 5mg prednisone/prednisolone bid.
- •3.Pathological finding consistent with small cell carcinoma of the prostate.
- •4.Liver or visceral organ metastasis.
- •5.Known brain metastasis.
- •6.Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1.
- •7.Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC.
- •8.Radiation therapy for treatment of the primary tumor within 6 weeks of Cycle 1, Day 1.
- •9.Radiation or radionuclide therapy for treatment of metastatic CRPC.
- •10.Previously treated with ketoconazole for prostate cancer for greater than 7 days.
- •11.Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of Cycle 1, Day 1.
- •12.Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1, Day 1 (patients whose PSA did not decline for three or more months in response to antiandrogen given as a second line or later intervention will require only a two week washout prior to Cycle 1, Day 1).
- •13.Bicalutamide (Casodex), nilutamide (andron) within 6 weeks of Cycle 1 Day 1 (patients whose PSA did not decline for three or more months in response to antiandrogen given as a second line or later intervention will require only a two week washout prior to Cycle 1, Day 1).
- •14.Uncontrolled hypertension (systolic BP = 160 mmHg or diastolic BP = 95 mmHg). Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.
- •15.Active or symptomatic viral hepatitis or chronic liver disease.
- •16.History of pituitary or adrenal dysfunction.
- •17.Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 50% at baseline.
- •18.Atrial Fibrillation, or other cardiac arrhythmia requiring therapy.
- •19.Other malignancy, except non-melanoma skin cancer, with a = 30% probability of recurrence within 24 months.
- •20.Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1.
- •21.Any condition which, in the opinion of the investigator, would preclude participation in this trial.
研究者
相似试验
招募中
3 期
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancermetastatic prostate cancer10038597NL-OMON38355Janssen-Cilag International NV35
招募中
1 期
A clinical study of ABSK021 in Patients with Tenosynovial Giant Cell Tumor to determine whether the study drug is safe and how well the antitumor activity of study drugTenosynovial Giant Cell TumorCTIS2023-503245-58-00Abbisko Therapeutics Co. Ltd.95
进行中（未招募）
1 期
Study to determine clinical benefit and safety of abiraterone acetate and prednisolone in patients with cancer of the prostate gland who have failed chemotherapy.EUCTR2007-005837-13-ESCougar Biotechnology, Inc
已完成
3 期
Phase 3 Study of Ravulizumab in Thrombotic Microangiopathy Associated With a Triggerthrombotic microangiopathy (TMA) associated with a triggerThrombotic Microangiopathy TMAJPRN-jRCT2031210494Yokosawa Jun100
进行中（未招募）
不适用
Study to determine clinical benefit and safety of abiraterone acetate and prednisolone in patients with cancer of the prostate gland who have failed chemotherapyEUCTR2007-005837-13-DEJanssen Oncology, Inc.1,158